The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Filtronic the leader in high-performance mmWave technologies, has today signed a Strategic Partnership and commercial agreement with SpaceX, a market leader in the low Earth Orbit market.
The Strategic Partnership includes the ongoing supply of Filtronic’s cutting-edge E-band Solid State Power Amplifiers (SSPA), alongside collaborative efforts in developing and delivering comparable products across multiple frequency bands core to SpaceX’s Starlink platform.
The agreement was signed with an initial order of $19.7m (£15.8m) to supply E-band SSPA modules, scheduled for delivery in FY2025, with further order flow expected to continue thereafter to support the ongoing deployment of SpaceX’s Starlink constellation, which provides high-speed, low-latency internet to users all around the world.
As part of the partnership, SpaceX has committed to ongoing orders for the next five years to ensure Filtronic remains a key part of its supply chain.
Richard Gibbs, Chief Executive Officer, of Filtronic, commented: “We are delighted to enter into this important Strategic Agreement with SpaceX, a market leader in LEO satellite constellations. This ongoing SpaceX partnership underlines our core value proposition of high-performance mmWave and operational excellence. It also provides Filtronic with the opportunity to scale manufacturing, build capability and execute our technology roadmap. The team at Filtronic are excited to develop our existing relationship with SpaceX and secure the ongoing supply of E-band SSPAs. We also look forward to collaborating with the SpaceX engineering team to develop new products for use in the Starlink system.”
Mike Nicolls, SpaceX’s Vice President of Starlink Engineering commented: “Filtronic has been an outstanding supplier for Starlink. They have matched our rate ramp and increasing demand for high-quality parts. Their strong engineering teams have taken ownership of their production process to meet our needs, taking their designs from wafer to functional unit, and are delivering quality parts in E-band which will enable the Starlink network to continue to grow and connect millions of more people around the world with high-speed, low-latency broadband internet.”
The Checkpoint Kinase 1 (Chk1) programme was initiated and advanced into first clinical trials in collaboration with the Institute of Cancer Research and the CRT Pioneer Fund. The clinical candidate drug, SRA737 (formerly CCT245737), is one of the most advanced Chk1 inhibitors in the clinic, is highly selective for Chk1 and is administered orally. Two Phase 1/2 clinical trials for the candidate drug have been completed in genetically selected patients with advanced cancers, conducted by former licence partner, Sierra Oncology:
a monotherapy study evaluating SRA737 in patients with tumours identified to have genetic aberrations hypothesised to confer sensitivity to Chk1 inhibition, including ovarian, prostate, non-small cell lung, head & neck, anus, and colorectal cancers. For more information click here
a drug combination study evaluating SRA737 potentiated by low-dose gemcitabine (LDG) in four cancer indications, including ovarian, small cell lung, sarcoma, and cervical/anogenital. For more information on the trial click here
Preliminary safety & efficacy data support further development of SRA737+LDG for the treatment of anogenital cancer. Additionally, preclinical data demonstrates synergy of SRA737 and SRA737+LDG in combinations with immune checkpoint, Poly ADP Ribose Polymerase (PARP) and DNA polymerase inhibitors.
Sierra Oncology was acquired by GlaxoSmithKline (GSK) in July 2022. In October 2022, GSK communicated its intention to return the rights to SRA737 to the CRT Pioneer Fund. SRA737 was subsequently licensed to a private US-based biopharma company in January 2024.
Nice 60 million buys. Moving north
Can’t buy any …buying pressure .. something brewing
Let the weak 0.02p seller cleared them sp will rise fast.
Nice & steady rise… 002P ++++ soon
2x 50 million buys. Big buys going on… something coming big
Up 14%….
Massive buys going on… something big coming in
Limited buys only at full ask… tick up soon
Holding nicely…. 40 million buys
It is a 24hr Operation with back to back crews covering day/night shifts.
The HE1 Rukwa Project has been derisked by the 2021 drilling campaign, which identified helium shows across multiple prospective intervals proving and established working helium system.